News and Analysis

Sonoma Biotherapeutics rakes in Series A

South San Francisco and Seattle-based Sonoma Biotherapeutics, a developer of regulatory T-cell therapies for autoimmune and degenerative diseases, has raised $30 million from investors in its Series A financing, bringing the total to $70 million.

-

South San Francisco and Seattle-based Sonoma Biotherapeutics, a developer of regulatory T-cell therapies for autoimmune and degenerative diseases, has raised $30 million from investors in its Series A financing, bringing the total to $70 million. The investors included Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments and the JDRF T1D Fund.

Source: Press Release